GPT and Hyperbilirubinemia: Although lapatinib has an acceptable safety profile in clinical settings, grade 3 alanine aminotransferase (ALT) elevation and serious liver injury with hyperbilirubinemia have been reported in 1.6% and 0.2%, respectively [3].